MIRA Pharmaceuticals Inc. (MIRA)
NASDAQ: MIRAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
MIRA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $31.33M
- EPS (TTM)
- -$1.21
- Dividend yield
- None
- 52-week range
- 0.60 – 2.45
- Day range
- 0.703 – 0.7498
- Volume / Avg
- 51.65K / 585.75K
- Beta
- —
- Shares outstanding
- 42.02M
52-week range
MIRA stock today
On Oct 9, MIRA ended the session at $0.7455, adding $0.0425 (6.05%), versus the S&P 500's 0.59% gain. Trading was light, with 51.65K shares changing hands, about 9% of the average daily volume. Shares are 69.6% below their 52-week high of $2.45, set on Oct 16, 2025 and 24.3% above the 52-week low of $0.60, near the bottom of the past year's range.
MIRA is down 50.6% year to date, underperforming the S&P 500 (+14.2%). Over the past 12 months, the stock has lost 44.4%. MIRA Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$1.21), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About MIRA Pharmaceuticals
Company profileMIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a next-generation oral NMDA receptor modulator, that has completed a Phase 1 clinical trial.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Erez Aminov
- Headquarters
- Miami, FL
- IPO year
- 2023
- Website
- mirapharmaceuticals.com
Analyst forecast
ForecastConsensus (1 analysts)
none
Avg. price target
$3.50+369.48%
- Strong buy 1
- Buy 0
- Hold 0
- Sell 0
- Strong sell 0
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
MIRA Pharmaceuticals peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| RNAZTransCode Therapeutics Inc. | 1.86 | +8.77% | $31.49M | vs MIRA |
| RMTIRockwell Medical Inc. | 7.89 | -1.62% | $31.80M | vs MIRA |
| NXTCNextCure Inc. | 7.18 | +5.90% | $32.87M | vs MIRA |
| NNVCNanoViricides Inc. | 1.30 | -0.76% | $33.18M | vs MIRA |
| IGCIGC Pharma Inc. | 0.2799 | -1.75% | $28.94M | vs MIRA |
| BCTXBriaCell Therapeutics Corp. | 3.91 | -0.13% | $34.02M | vs MIRA |
| ATNMActinium Pharmaceuticals Inc. (Delaware) | 1.10 | +1.85% | $34.59M | vs MIRA |
| CNTXContext Therapeutics Inc. | 0.3042 | +1.74% | $27.95M | vs MIRA |
Indexes, lists and sector
MIRA Pharmaceuticals stock FAQ
What is MIRA Pharmaceuticals's stock price today?
MIRA last traded at $0.7455 as of Oct 9, 4:00 PM EDT, up 6.05% on the day. Prices are delayed at least 15 minutes.
Who is MIRA Pharmaceuticals's CEO?
Mr. Erez Aminov is the chief executive officer of MIRA Pharmaceuticals Inc..
What is the MIRA 52-week high?
The 52-week high for MIRA is $2.45 and the 52-week low is $0.60. The stock is currently 69.6% below its high.